Tag archief: English Only

Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018

SUMMIT, N.J.–(BUSINESS WIRE)– 82% overall response rate observed in heavily pre-treated patients 9% of patients experienced grade 3/4 cytokine release syndrome; 7% experienced a grade...

Oxford BioMedica Notes the Longer-Term Analyses from Pivotal Kymriah® Trials, Which Showed Durable Responses Are Maintained in Patients with Advanced Blood Cancers

OXFORD, England–(BUSINESS WIRE)– Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis...

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018

Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in significant reduction of transfusion burden compared to placebo Regulatory submissions planned in the United...

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Eighty one percent overall response rate and 43% complete response rate observed in heavily pre-treated patients Majority of patients evaluable for minimal residual disease achieved...

Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma

— 39 Percent of Patients in Ongoing Response Two Years after a Single Infusion of Yescarta in the ZUMA-1 Study; Median Overall Survival was Not...

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session

Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo Regulatory submissions planned...

European Medicines Agency Accepts Extension Marketing Authorisation Application for Review of Celltrion’s Remsima SC, the Subcutaneous Version of Remsima®

European Medicines Agency started to officially review ‘Remsima SC’; expecting European approval in the second half of next year INCHEON, South Korea–(BUSINESS WIRE)–Celltrion, Inc. (KRX:068270)...

NTT Communications Expands Its DDoS Protection Services with New Auto-Mitigation Solution

Global IP Network Customers Can Choose the Level of Mitigation Support that Best Fits their Cyber Security Strategy NEW YORK–(BUSINESS WIRE)–NTT Communications Corporation (NTT Com),...

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo Positive trend in overall survival was observed Regulatory submissions...

Marriott Announces Starwood Guest Reservation Database Security Incident

BETHESDA, Md.–(BUSINESS WIRE)– Marriott has taken measures to investigate and address a data security incident involving the Starwood guest reservation database. On November 19, 2018, the...

Tokyo Gas Switches to Rimini Street Support for SAP Applications

LAS VEGAS–(BUSINESS WIRE)– Leading energy provider in Japan maximizes ROI on key SAP system while receiving premium-level support Rimini Street, Inc. (Nasdaq: RMNI), a global provider...

PKU GOLIKE® Comes to Fruition in Italy

BALERNA, Switzerland–(BUSINESS WIRE)– PKU GOLIKE®, the brand new generation of Phenylalanine (PHe)-free medical food formula for Phenylketonuria (PKU) dietary management, powered by the patented drug...

Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to

LONDON–(BUSINESS WIRE)– Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in these young patients Vertex...

Gemalto Unveils Industry’s First Cloud Access Management and Single Sign on Solution Enhanced for Smart Card Users

AMSTERDAM–(BUSINESS WIRE)– SafeNet Trusted Access now supports smart card credentials access for cloud apps and brings PKI technology to cloud and digital transformation initiatives Gemalto...

Seoul Semiconductor Expands Patent Infringement Litigation against LED TV Distributor, Asserting Infringement of 19 LED Patents

ANSAN, South Korea–(BUSINESS WIRE)– Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a leading global innovator of LED products and technology, announced that it has expanded its patent...